48,453
edits
Difference between revisions of "Hepatitis B"
Jump to navigation
Jump to search
no edit summary
| (4 intermediate revisions by the same user not shown) | |||
| Line 7: | Line 7: | ||
| Micro = lobular inflammation - hepatocyte necrosis, +/-[[ground glass hepatocytes]] | | Micro = lobular inflammation - hepatocyte necrosis, +/-[[ground glass hepatocytes]] | ||
| Subtypes = | | Subtypes = | ||
| LMDDx = [[hepatitis C]], [[autoimmune hepatitis]], [[primary biliary cirrhosis]] without [[granulomas]], [[drug-induced liver disease| | | LMDDx = [[hepatitis C]], [[autoimmune hepatitis]], [[primary biliary cirrhosis]] without [[granulomas]], [[drug-induced liver disease|drug reaction]] | ||
| Stains = | | Stains = [[Shikata stain]] +ve (not sensitive) | ||
| IHC = | | IHC = hepatitis B +ve | ||
| EM = | | EM = | ||
| Molecular = | | Molecular = HBV DNA present (serum) | ||
| IF = | | IF = | ||
| Gross = | | Gross = | ||
| Line 23: | Line 23: | ||
| Symptoms = | | Symptoms = | ||
| Prevalence = common - especially in Asia | | Prevalence = common - especially in Asia | ||
| Bloodwork = | | Bloodwork = HBs Ag, HBs Ab, HBe Ag, HBe Ab - see ''[[Medical_liver_disease#Hepatitis_B]]'' | ||
| Rads = | | Rads = | ||
| Endoscopy = | | Endoscopy = | ||
| Prognosis = | | Prognosis = | ||
| Other = | | Other = | ||
| ClinDDx = | | ClinDDx = other hepatitides - viral and non-viral | ||
| Tx = | | Tx = prevention through vaccination, medical treatments (pegylated interferon and nucleoside analogues) | ||
}} | }} | ||
'''Hepatitis B''' is a relatively common [[medical liver disease]] caused by the ''hepatitis B virus''. | '''Hepatitis B''' is a relatively common [[medical liver disease]] caused by the ''hepatitis B virus''. | ||
| Line 37: | Line 37: | ||
*High prevalence. | *High prevalence. | ||
*Diagnosis is by serology - details of serologic testing are in the ''[[Medical_liver_disease#Hepatitis_B|medical liver disease article]]''. | *Diagnosis is by serology - details of serologic testing are in the ''[[Medical_liver_disease#Hepatitis_B|medical liver disease article]]''. | ||
*A vaccination is available and done routinely in a many jurisdictions.<ref>{{Cite journal | last1 = Leuridan | first1 = E. | last2 = Van Damme | first2 = P. | title = Hepatitis B and the need for a booster dose. | journal = Clin Infect Dis | volume = 53 | issue = 1 | pages = 68-75 | month = Jul | year = 2011 | doi = 10.1093/cid/cir270 | PMID = 21653306 }}</ref> | *A vaccination is available and done routinely in a many jurisdictions.<ref name=pmid21653306>{{Cite journal | last1 = Leuridan | first1 = E. | last2 = Van Damme | first2 = P. | title = Hepatitis B and the need for a booster dose. | journal = Clin Infect Dis | volume = 53 | issue = 1 | pages = 68-75 | month = Jul | year = 2011 | doi = 10.1093/cid/cir270 | PMID = 21653306 }}</ref> | ||
*Medical treatments available for chronic infection - pegylated interferon and nucleoside analogue therapies.<ref>{{Cite journal | last1 = Su | first1 = TH. | last2 = Kao | first2 = JH. | title = Unmet Needs in Clinical and Basic Hepatitis B Virus Research. | journal = J Infect Dis | volume = 216 | issue = suppl_8 | pages = S750-S756 | month = Nov | year = 2017 | doi = 10.1093/infdis/jix382 | PMID = 29156048 }}</ref><ref name=pmid28052634>{{Cite journal | last1 = Chen | first1 = GF. | last2 = Wang | first2 = C. | last3 = Lau | first3 = G. | title = Treatment of chronic hepatitis B infection-2017. | journal = Liver Int | volume = 37 Suppl 1 | issue = | pages = 59-66 | month = Jan | year = 2017 | doi = 10.1111/liv.13309 | PMID = 28052634 }}</ref> | |||
Associated pathology | ===Associated pathology=== | ||
*[[Polyarteritis nodosa]] (PAN). | *[[Polyarteritis nodosa]] (PAN). | ||
*[[Membranoproliferative glomerulonephritis]]. | *[[Membranoproliferative glomerulonephritis]]. | ||
*[[Membranous nephropathy]]. | *[[Membranous nephropathy]]. | ||
*[[Cirrhosis]]. | |||
*[[Hepatocellular carcinoma]]. | |||
==Microscopic== | ==Microscopic== | ||